AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 AUG 22 - (NewsRx.com & NewsRx.net) --
by Deborah W. Heinrich, PhD, staff medical writer - A novel DNA vaccine using a plant viral protein to stimulate immunity offers hope against myeloma and lymphoma, say researchers in the U.K.
"DNA delivery of tumor antigens can activate specific immune attack on cancer cells," explained Natalia Savelyeva and colleagues in a paper published in the August 2001 issue of Nature Biotechnology. In theory, this would be an excellent anticancer therapy for malignancies such as myeloma and lymphoma in which idiotypic B-cell determinants derived from variable regions could be delivered as clone specific tumor antigens. In reality, however, this approach is limited because the tumor antigens are weak immune stimulators.
To enhance immunogenicity, Savelyeva and research team took advantage of the antigenic properties of the tetanus toxoid. In previous work, they fused an idiotypic B cell antigen gene to the tetanus toxoid gene and found the resulting DNA vaccine to protect against lymphoma and myeloma. In a more recent study involving researchers from the Molecular Immunology Group, Tenovus Laboratory, Southampton, U.K. and the John Innes Centre, Norwich, U.K., Savelyeva and coworkers chose an alternate immune stimulator for fusion with the B-cell tumor antigen. It was their hope to obtain higher levels of protection by stimulating appropriate effector pathways.
In this case, the ...
Source: HighBeam Research, Plant Viral Proteins Enhance Idiotypic Antigenicity In DNA...